News & Updates
Filter by Specialty:
INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD
Findings from the open-label extension (OLE) phase of the INCREASE study boost the efficacy and safety of inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD).
INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD
31 May 2022
MS patients on certain DMTs may have limited protection from COVID-19 vax
The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.
MS patients on certain DMTs may have limited protection from COVID-19 vax
30 May 2022
Acid reflux drug fails to show benefit in pre-eclampsia treatment
Omeprazole falls short of improving the maternal circulating profile of sFlt-1 (soluble Fms-like tyrosine kinase-1), PlGF (placental growth factor), and ET-1 (endothelin-1) in women with established pre-eclampsia, as shown in a study.
Acid reflux drug fails to show benefit in pre-eclampsia treatment
29 May 2022
Accelerated daratumumab infusion safe, well tolerated in multiple myeloma
Accelerated administration of daratumumab, an anti-CD3 monoclonal antibody approved for multiple myeloma, is safe and well tolerated when given following at least two standard infusions, suggest the results of a recent study.
